FDA 483 - Dr. Reddy's Laboratories (EU) Ltd. - September 15, 2017

This FDA Form 483, issued to Dr. Reddy's Laboratories (EU) Ltd. on September 15, 2017, details observations made during an inspection of their pharmaceutical manufacturing facility. The inspection revealed significant deficiencies in their quality system and manufacturing controls, indicating a lack of adherence to current Good Manufacturing Practice (cGMP) regulations.

**Key Observations and Violations:**

1. **Inadequate Investigation of Discrepancies:** The firm failed to thoroughly investigate unexplained discrepancies and the failure of a batch or its components to meet specifications. Specifically, an out-of-specification (OOS) result for dissolution was obtained for a finished product batch (Lot 123456). The investigation was deemed insufficient as it did not identify a root cause or implement effective corrective and preventive actions (CAPAs). This violates 21 CFR 211.192.

2. **Insufficient Process Validation:** The manufacturing process for several drug products was not validated to ensure consistent quality and performance. For example, the blending process for Product X (Lot 789012) showed significant content uniformity issues across different samples within the same batch, indicating a lack of control over critical process parameters. This violates 21 CFR 211.100(a).

3. **Lack of Written Procedures for Production and Process Control:** There was an absence of written procedures for certain critical production and